A series of 14 metastatic UMV patients was treated with dendritic cell vaccination, using antigen-presenting cells loaded with gp100 and tyrosinase: a tumor specific response was observed in 29% of the patients, while median overall survival was 19.2 months [86]. This evidence concerns the gene TYR and neoplasm.